An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completion among adults in the UK
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Rifapentine (Primary) ; Isoniazid/rifampicin
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms RID-TB:Treat
- 11 Dec 2020 New trial record